Free daily briefing on global business news.
The drug remains in Phase 3 clinical trials and has not been approved by any regulator for human use
jetcityimage / Getty Images
Eli Lilly $LLY filed six lawsuits Wednesday against U.S. companies it accuses of selling black-market versions of its experimental weight loss drug retatrutide, which has not been approved by any regulatory agency for human use.
Among those sued are compounding pharmacies, medical spas, and online vendors that Lilly alleges offered retatrutide to consumers even as the drug continues to move through Phase 3 trials for obesity, type 2 diabetes, and related conditions. The defendants are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co., the company said.
